Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $68.6667.

GPCR has been the subject of a number of analyst reports. Zacks Research lowered Structure Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a report on Monday, November 24th. Finally, JMP Securities decreased their price target on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th.

Structure Therapeutics Stock Up 4.6%

NASDAQ GPCR opened at $35.81 on Friday. The firm has a market cap of $2.07 billion, a P/E ratio of -29.35 and a beta of -1.63. The company’s 50 day moving average is $30.55 and its 200-day moving average is $23.98. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $40.29.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Equities analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Balyasny Asset Management L.P. purchased a new position in shares of Structure Therapeutics during the third quarter worth about $12,923,000. Pacific Heights Asset Management LLC purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $9,540,000. Orbimed Advisors LLC lifted its position in Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after purchasing an additional 397,272 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Structure Therapeutics in the 3rd quarter worth approximately $10,440,000. Finally, Casdin Capital LLC increased its holdings in shares of Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after buying an additional 330,000 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.